Disclosed is a humanized anti-FGF19 antibody comprising: (i) a light chain comprising (a) hypervariable region (HVR)-L1 sequences comprising sequence A1-A11, wherein A1-A11 is KASQDINSFLA (SEQ ID NO:11)； (b) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is RANRLVD (SEQ ID NO:2), RANRLVS (SEQ ID NO:13), or RANRLVE (SEQ ID NO:14)； and (c) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is LQYDEFPLT (SEQ ID NO:3)； and (ii) a heavy chain comprising (a) HVR-H1 comprising sequence D1 -D10, wherein Dl-D10 is GFSLTTYGVH (SEQ ID NO:4)； (b) HVR-H2 comprising sequence El-E17, wherein El-E17 is GVIWPGGGTDYNAAFIS (SEQ ID NO:7)； and (c) HVR-H3 comprising sequence Fl-F13, wherein Fl-F13 is VRKEYANLYAMDY (SEQ ID NO:8). Also disclosed is the use of the antibody in the preparation of a medicament for treatment of a tumor, a cancer or a cell proliferation disorder.
